# A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

> **NCT06077760** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 868 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Intismeran autogene
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06077760
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2030-06-25
- **Final completion:** 2035-12-21
- **Target enrollment:** 868 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- ModernaTX, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06077760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06077760, "A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06077760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*